


Author's Accepted Manuscript

Under explored epigenetic modulators: role in glioma chemotherapy

Yan-Hong Chen, Wen-jing Zeng, Zhi-peng Wen, Quan Chen, Xiao-Ping Chen



PII: S0014-2999(18)30318-2
DOI: <https://doi.org/10.1016/j.ejphar.2018.05.047>
Reference: EJP71829

To appear in: *European Journal of Pharmacology*

Received date: 4 March 2018
Revised date: 31 May 2018
Accepted date: 31 May 2018

Cite this article as: Yan-Hong Chen, Wen-jing Zeng, Zhi-peng Wen, Quan Chen and Xiao-Ping Chen, Under explored epigenetic modulators: role in glioma chemotherapy, *European Journal of Pharmacology*, <https://doi.org/10.1016/j.ejphar.2018.05.047>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Under explored epigenetic modulators: role in glioma chemotherapy

Yan-Hong Chen^{a,b}, Wen-jing Zeng^{a,b}, Zhi-peng Wen^{a,b}, Quan Chen^{a,b}, Xiao-Ping
Chen^{a,b*}

^aDepartment of Clinical pharmacology, Xiangya Hospital, Central south university,
Changsha, 410078, China;

^bInstitute of Clinical pharmacology, Central south university, Hunan Key Laboratory
of Pharmacogenetics, Changsha, 410078, China;

***Corresponding author.** Professor Xiao-Ping Chen. Department of Clinical
pharmacology, Xiangya Hospital, Central south university, Changsha, 410078, China,
No.110 Xiangya Road, Changsha, Hunan 410008, China Tel.: 86-731-84805380;
fax:86-731-82355078. chenxp74@hotmail.com

Abstract

Patients with somatic mutations of epigenetic regulators are characterized by aberrant chromatin modification patterns. Recent mechanistic studies pairing chemical tool compounds and deep-sequencing technology have greatly broadened our understanding of epigenetic regulation in glioma progression and underpinned alternative treatment of epigenetic inhibitors. However, the effect of most inhibitors is condition-dependent, and the overall results of clinical trials still have not been

Download English Version:

<https://daneshyari.com/en/article/8528901>

Download Persian Version:

<https://daneshyari.com/article/8528901>

[Daneshyari.com](https://daneshyari.com)